Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on June 10, 2022, covering events occurring on June 6 and June 8, 2022. The filing details executive compensation arrangements related to a workforce reduction and the results of the Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on specific executive compensation awards and stockholder voting results.
Material Changes and Executive Compensation
In connection with a workforce reduction announced in April 2022, the Board approved a retention program. On June 6, 2022, the Compensation Committee approved a letter agreement with Chief Financial Officer David Spellman containing the following terms:
- Retention Bonus: A cash payment of $100,000, subject to repayment if Mr. Spellman voluntarily terminates or is terminated for cause within 12 months.
- Performance Bonus: An opportunity to earn up to $250,000 in cash upon achieving certain milestones.
- Equity Grants: On June 8, 2022, Mr. Spellman received 200,000 Restricted Stock Units (RSUs) and options to purchase 200,000 shares. These vest in full on May 12, 2023, contingent on continuous employment, with acceleration provisions for change in control or termination without cause.
Stockholder Voting Results
The Annual Meeting of Stockholders held on June 8, 2022, resulted in the following outcomes:
- Director Elections: Two Class II directors were elected to serve until 2025.
- John P. Butler: 45,002,965 votes for; 20,443,013 votes withheld.
- Myles Wolf, M.D., M.M.Sc.: 41,568,017 votes for; 23,877,961 votes withheld.
- Executive Compensation (Say-on-Pay): Approved on a non-binding advisory basis with 54,224,141 votes for and 10,859,388 votes against.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm with 105,575,630 votes for and 3,184,168 votes against.
Investor Verification Checklist
- Verify the full text of the Letter Agreement with David Spellman, which is expected to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2022.
- Review the specific milestones required to earn the $250,000 performance bonus for the CFO.
- Monitor the upcoming Form 10-Q for details on the financial impact of the April 2022 workforce reduction and the associated retention costs.
- Confirm the vesting schedule and acceleration triggers for the 400,000 total equity units granted to the CFO.